Express Pharma

OCTOBER 10, 2023

In May 2023, Alvotech and Advanz Pharma announced an extended strategic partnership with plans to supply and commercialise five proposed biosimilars in Europe, including Simponi. This global study positions AVT05 as the leading contender for Simponi biosimilars in the rheumatoid arthritis (RA) market, says GlobalData.

Biosimilars 52

Biosimilars 52

STAT

JANUARY 8, 2024

Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge.

Medicine Expiration 266

Medicine Expiration Biosimilars 266

pharmaphorum

SEPTEMBER 20, 2022

Novartis’ soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen’s blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory filings. Other companies working on biosimilar versions of denosumab include Samsung Bioepis, Celltrion, and AryoGen Pharmed.

Biosimilars 52

Biosimilars 52

pharmaphorum

JULY 18, 2022

Polpharma has become the first company to file for approval in the EU of a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri. It had expected the drug would not face biosimilar competition in Europe until at least 2027.

Biosimilars 52

Biosimilars 52

pharmaphorum

SEPTEMBER 20, 2021

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Lucentis (ranibizumab) for leading causes of blindness, raising the prospect of a cheaper treatment option for US patients. Sales reached a peak in 2019, when Roche booked $1.8 billion, but fell back to $1.4

Biosimilars 72

Biosimilars Labelling Diabetes 72

European Pharmaceutical Review

DECEMBER 19, 2022

A biosimilar is a biological medicine ‘similar’ to another biological medicine already approved in the EU (the ‘reference medicine’). 1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product.

Biosimilars 52

Biosimilars 52

Big Molecule Watch

MAY 22, 2023

Last week, Amneal announced the launch of FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA, in the United States. Amneal developed FYLNETRA in collaboration with Kashiv Biosciences, a biopharmaceutical company located in Chicago, Illinois.

Biosimilars 70

Biosimilars Chemotherapy 70

Big Molecule Watch

APRIL 20, 2023

On Monday April 17, 2023, Celltrion announced that it has launched VEGZELMA (bevacizumab-adcd, an AVASTIN biosimilar) in the United States for the treatment of several cancers, including metastatic colorectal cancer and breast cancer. As we previously reported , VEGZELMA was approved by the U.S. pharmaceutical market.

Biosimilars 70

Biosimilars 70

Safe Biologics

MAY 10, 2023

On May 9th, GaBI Journal published a whitepaper titled “Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars”, based on the recent survey of 41 Canadian ophthalmologists by ASBM and the International Federation on Ageing (IFA). 79% of Canadian, 84% of European, and 67% of U.S.

Biosimilars 100

Biosimilars 100

Safe Biologics

MAY 10, 2023

On May 9th, GaBI Journal published a whitepaper titled “Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars”, based on the recent survey of 41 Canadian ophthalmologists by ASBM and the International Federation on Ageing (IFA). 79% of Canadian, 84% of European, and 67% of U.S.

Biosimilars 100

Biosimilars 100

pharmaphorum

AUGUST 23, 2021

Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis’ copycat drug Byooviz. Sales reached a peak in 2019, when Roche booked $1.8 billion in sales from the drug while Novartis made $2.1 billion for Roche and $1.9

Biosimilars 40

Biosimilars Diabetes 40

pharmaphorum

OCTOBER 1, 2020

Adalimumab – sold by AbbVie as Humira as well as in biosimilar form by companies including Novartis’ Sandoz unit, Amgen and Biogen/Samsung joint venture Bioepis – will be used in the phase 2 AVID-CC study to see if it can prevent progression to respiratory failure in people with coronavirus infections.

Biosimilars 70

Biosimilars Hospitals Inpatient 70

STAT

NOVEMBER 1, 2023

The FDA approved Amgen’s biosimilar version of Johnson & Johnson’s blockbuster psoriasis treatment, Stelara, for multiple inflammatory diseases , Reuters says. Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022.

Biosimilars 213

Biosimilars 213

Pharma Pathway

FEBRUARY 26, 2023

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Hetero also offers custom pharmaceutical services to its partners around the world.

Biosimilars 85

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 85

Pharma Pathway

JANUARY 7, 2023

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Pass out year: 2019/ 20/ 21/ 22 Passed outs. Experience: Freshers.

Biosimilars 88

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 88

Pharma Pathway

FEBRUARY 14, 2023

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Hetero also offers custom pharmaceutical services to its partners around the world.

Biosimilars 84

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 84

Pharmaceutical Technology

MARCH 8, 2023

This is the second time Lilly has significantly reduced the cost of its insulin, as in 2019 the company reduced the list price of Humalog by 50%. These two insulin therapies have been off patent for about a decade but have a list price of about $500 for a pack of five injection pens and currently have limited competition from biosimilars.

Biosimilars 105

Biosimilars Diabetes 105

Pharma Pathway

DECEMBER 13, 2022

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Pass out year: 2019/ 2020/2021/ 2022. Dear, Greetings from Hetero…!!

Biosimilars 80

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 80

Pharma Pathway

FEBRUARY 20, 2023

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Hetero also offers custom pharmaceutical services to its partners around the world.

Biosimilars 78

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 78

Big Molecule Watch

MARCH 13, 2023

On March 6, 2023, Coherus Biosciences announced FDA approval of an autoinjectable version of Udenyca, Coherus’ biosimilar to Amgen’s Neulasta (pegfilgrastim). Udenyca (pegfilgrastim-cbqv) was first launched in the US in January 2019 and is one of six FDA approved pegfilgrastim biosimilars.

Biosimilars 52

Biosimilars Chemotherapy 52

Pharma Pathway

FEBRUARY 2, 2023

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Hetero also offers custom pharmaceutical services to its partners around the world.

Biosimilars 80

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 80

Pharma Pathway

SEPTEMBER 16, 2022

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Experience: 2019, 2020, 2021, 2022 passed outs only. Designation: Jr.

Biosimilars 79

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 79

Pharma Pathway

SEPTEMBER 13, 2022

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Eligibility: 2019, 2020, 2021, 2022 passed outs Only. Greetings from Hetero…!!

Biosimilars 78

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 78

pharmaphorum

OCTOBER 13, 2022

ResearchandMarkets also recently published a report , which highlighted only biosimilars as the emerging treatments for osteoporosis. The therapy has been on the market in Europe since 2019, which is marketed by UCB in the region, though by Amgen and Astellas in other areas. Emerging research and biosimilars.

Biosimilars 92

Biosimilars Communication Pharmaceutical Companies Pharmaceutical Companies 92

Pharmaceutical Technology

FEBRUARY 3, 2023

However, after almost seven years of staving off competitors through patents and litigation, Humira’s market-leading position in the US will be affected as Amgen’s adalimumab biosimilar, Amjevita, started to roll out on January 31, 2023. According to GlobalData estimates, in 2022, the adalimumab biosimilars market was valued at $184.2

Biosimilars 52

Biosimilars Compounding 52

pharmaphorum

NOVEMBER 17, 2022

The 2019 VPAS , just like its predecessor that was in place from 2014, has at its heart a payback mechanism. That is why companies who are members of the 2019 VPAS have collectively paid back almost £3 billion to the Department of Health and Social Care (DHSC) up to Quarter 2 of 2022. Predictable for government. Variable for companies.

Biosimilars 98

Biosimilars 98

pharmaphorum

APRIL 13, 2022

According to research , one vial of Humalog (insulin lispro) cost $21 in 1999, but this increased to $332 in 2019, representing a price increase of 1480%. Potential biosimilar impact. Outside of Congress, there is another element that could reduce the cost of insulin, in the form of biosimilars. Innovation to end debate?

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

Pharma Pathway

FEBRUARY 4, 2023

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Hetero also offers custom pharmaceutical services to its partners around the world.

Biosimilars 52

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 52

Pharma Pathway

SEPTEMBER 23, 2022

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Pass out year: 2019 -2022 Pass outs. Qualification: M.Sc/ B.Sc/ MBA HR.

Biosimilars 52

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 52

Pharma Pathway

SEPTEMBER 12, 2022

Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. Eligibility: 2018, 2019, 2020, 2021, 2022 passed outs Only. Chemist/ Jr.

Biosimilars 52

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 52

STAT

NOVEMBER 18, 2022

As of 2019, about 1.9 Diabetic patients will now have easier access to insulin after the FDA approved an Eli Lilly biosimilar as interchangeable with the biologic drug , Bloomberg News notes. The treatment comes as a 14-day course of infusions that each last 30 to 60 minutes. million people have type 1 diabetes in the U.S.,

Diabetes 194

Diabetes Biosimilars Documentation Compounding 194

pharmaphorum

NOVEMBER 16, 2022

Novartis completed the spin-out of Alcon in 2019, separating products like contact lenses and over-the-counter eyedrops from its prescription eye medicines, headed by age-related macular degeneration (AMD) blockbuster Lucentis (ranibizumab), which is partnered with Roche. billion in the first nine months of this year.

Biosimilars 123

Biosimilars Diabetes 123

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

pharmaphorum

DECEMBER 13, 2020

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

Biosimilars 109

Biosimilars 109

pharmaphorum

FEBRUARY 24, 2021

Higher biosimilar savings. Spain, like many European countries, have seen biosimilars as a route to helping manage pressure on health care spending. Back in 2020 savings from biosimilars were forecasted to really get going in that year and through to 2022. The post 2021 market access prospects for Spain appeared first on.

Biosimilars 78

Biosimilars Immunity Immunization 78

pharmaphorum

DECEMBER 15, 2022

of total sales – under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) introduced in 2019. “Despite the UK’s competitive market already delivering the lowest prices in Europe, regulation means branded generics and biosimilars are subsumed into the VPAS scheme.” VPAS tax on top.

Biosimilars 72

Biosimilars 72

pharmaphorum

SEPTEMBER 8, 2020

In my role at Sandoz, I work with teams that are passionately trying to drive healthcare sustainability through the increased use of high-quality biosimilars. 7 With a typical price difference between reference biologics and biosimilars in the range of -15% to -80%, the immediate potential budget impacts are in the tens of billions.

Biosimilars 77

Biosimilars Drug Pricing Chemotherapy Vaccines 77